LifeVantage (LFVN) Competitors $15.09 -0.19 (-1.24%) (As of 11:38 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends LFVN vs. TRDA, TECX, DNTH, ANAB, ORIC, ABUS, TRML, ESPR, TSHA, and PHVSShould you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Entrada Therapeutics (TRDA), Tectonic Therapeutic (TECX), Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), ORIC Pharmaceuticals (ORIC), Arbutus Biopharma (ABUS), Tourmaline Bio (TRML), Esperion Therapeutics (ESPR), Taysha Gene Therapies (TSHA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. LifeVantage vs. Entrada Therapeutics Tectonic Therapeutic Dianthus Therapeutics AnaptysBio ORIC Pharmaceuticals Arbutus Biopharma Tourmaline Bio Esperion Therapeutics Taysha Gene Therapies Pharvaris LifeVantage (NASDAQ:LFVN) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends. Is LFVN or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to LifeVantage's net margin of 2.11%. LifeVantage's return on equity of 29.24% beat Entrada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage2.11% 29.24% 12.82% Entrada Therapeutics 25.53%16.11%10.39% Do analysts rate LFVN or TRDA? Entrada Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 18.11%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than LifeVantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor LFVN or TRDA? In the previous week, Entrada Therapeutics had 1 more articles in the media than LifeVantage. MarketBeat recorded 3 mentions for Entrada Therapeutics and 2 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.67 beat Entrada Therapeutics' score of 1.53 indicating that LifeVantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeVantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation & earnings, LFVN or TRDA? LifeVantage has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$200.16M0.96$2.94M$0.3247.75Entrada Therapeutics$215.23M3.53-$6.68M$1.5912.78 Does the MarketBeat Community prefer LFVN or TRDA? LifeVantage received 205 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Entrada Therapeutics an outperform vote while only 77.82% of users gave LifeVantage an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22177.82% Underperform Votes6322.18% Entrada TherapeuticsOutperform Votes1680.00% Underperform Votes420.00% Which has more volatility & risk, LFVN or TRDA? LifeVantage has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Do insiders & institutionals have more ownership in LFVN or TRDA? 35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 20.7% of LifeVantage shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryEntrada Therapeutics beats LifeVantage on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get LifeVantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.31M$7.05B$5.37B$8.94BDividend Yield1.10%7.97%5.33%4.05%P/E Ratio47.7511.27117.4718.00Price / Sales0.96242.101,426.31155.72Price / Cash16.5662.0542.7338.60Price / Book6.9110.647.356.66Net Income$2.94M$152.36M$118.37M$224.93M7 Day Performance11.13%3.48%3.40%2.50%1 Month Performance17.54%-1.31%2.49%10.24%1 Year Performance138.75%31.71%36.16%30.14% LifeVantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifeVantage3.7184 of 5 stars$15.09-1.2%N/A+138.8%$188.93M$200.16M47.16260Positive NewsGap UpTRDAEntrada Therapeutics1.9959 of 5 stars$19.94+0.3%$24.00+20.4%+51.6%$746.16M$215.23M12.49110Positive NewsGap UpTECXTectonic Therapeutic3.2744 of 5 stars$49.81+0.1%$72.25+45.1%N/A$734.85MN/A-8.45120Short Interest ↑DNTHDianthus Therapeutics1.9137 of 5 stars$24.13+0.6%$46.43+92.4%+128.0%$714.25M$2.83M-9.6080Short Interest ↑Positive NewsANABAnaptysBio2.4142 of 5 stars$22.97-8.0%$54.64+137.9%+62.5%$698.98M$17.16M-3.82100Analyst DowngradeShort Interest ↑News CoverageGap DownORICORIC Pharmaceuticals4.54 of 5 stars$9.79-1.1%$18.29+86.8%+23.0%$690.85MN/A-5.5080News CoveragePositive NewsABUSArbutus Biopharma2.922 of 5 stars$3.52+1.7%$5.50+56.3%+70.4%$667.01M$18.14M-8.0573Short Interest ↓TRMLTourmaline Bio2.2297 of 5 stars$25.39-2.5%$65.00+156.0%+35.1%$651MN/A-9.1344Positive NewsESPREsperion Therapeutics4.1086 of 5 stars$3.27+16.8%$8.17+149.7%+115.3%$644.32M$116.33M-4.64240Analyst ForecastShort Interest ↓Analyst RevisionTSHATaysha Gene Therapies4.0239 of 5 stars$3.13-3.4%$6.63+111.7%+67.4%$641.47M$9.92M5.14180PHVSPharvaris2.1187 of 5 stars$20.03-8.5%$33.60+67.7%+3.0%$637.76MN/A-6.9830Gap Down Related Companies and Tools Related Companies Entrada Therapeutics Competitors Tectonic Therapeutic Competitors Dianthus Therapeutics Competitors AnaptysBio Competitors ORIC Pharmaceuticals Competitors Arbutus Biopharma Competitors Tourmaline Bio Competitors Esperion Therapeutics Competitors Taysha Gene Therapies Competitors Pharvaris Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LFVN) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LifeVantage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LifeVantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
